RxDoctor Payments Data

Param Singh, MD

Interventional Cardiology · Moline, ILNPI 1275732133

Payments from drug & device makers

$1,451in general payments, 2019–2025

Across 31 payments — averaging $46.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$363
  • AstraZeneca$288
  • Inari Medical, Inc.$217
  • Amgen$106
  • Penumbra, Inc.$80
  • Edwards Lifesciences$77
  • plus $320 from 9 others

What the payments were for

  • Travel & lodging$22115%
  • Food & beverage$1,21784%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,451 in reported general payments places this provider in the 15th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,396,761
Medicare patients
2,134
Services billed
11,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban633$767,118
EntrestoSacubitril/Valsartan113$149,559
XareltoRivaroxaban98$122,742
Repatha SureclickEvolocumab47$59,472
MultaqDronedarone Hcl41$55,383
JardianceEmpagliflozin36$47,208
BrilintaTicagrelor47$38,654
FarxigaDapagliflozin Propanediol13$16,445
Ranolazine ErRanolazine85$13,592
Metoprolol Succinate1,100$12,716
Flecainide Acetate129$6,362
ClopidogrelClopidogrel Bisulfate617$6,075
Atorvastatin Calcium628$5,786
Carvedilol607$4,858
Losartan Potassium476$3,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$59$149,559113 claims
Sanofi-aventis U.S. LLCMultaq$38$55,38341 claims
AstraZenecaBrilinta, Farxiga$288$55,10060 claims
Boehringer IngelheimJardiance$29$47,20836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →